These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23317532)

  • 1. Authors' reply.
    Ballantyne CM; Bays HE; Braeckman RA; Soni PN
    Am J Cardiol; 2013 Feb; 111(3):455-6. PubMed ID: 23317532
    [No Abstract]   [Full Text] [Related]  

  • 2. ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.
    Baum SJ
    Am J Cardiol; 2013 Feb; 111(3):454-5. PubMed ID: 23317530
    [No Abstract]   [Full Text] [Related]  

  • 3. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
    Singh N; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Mason RP; Ballantyne CM;
    J Am Coll Cardiol; 2022 Jan; 79(2):220-222. PubMed ID: 35027114
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
    Paillard F
    Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119
    [No Abstract]   [Full Text] [Related]  

  • 8. Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
    Copple T; Ciffone NA
    Nurse Pract; 2017 Dec; 42 Suppl 12():3-9. PubMed ID: 29176336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the clinical benefits of lipid-disorder drugs.
    Hiatt WR; Smith RJ
    N Engl J Med; 2014 Jan; 370(5):396-9. PubMed ID: 24476429
    [No Abstract]   [Full Text] [Related]  

  • 10. The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.
    Steg PG; Bhatt DL
    Eur Heart J; 2021 Dec; 42(47):4865-4866. PubMed ID: 34734264
    [No Abstract]   [Full Text] [Related]  

  • 11. To treat or not to treat? Questions, controversies in prevention.
    Caffrey MK
    Am J Manag Care; 2014 May; 20(8 Spec No.):E11. PubMed ID: 25617930
    [No Abstract]   [Full Text] [Related]  

  • 12. Reaching hypertriglyceridemia goals.
    Katsiki N; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2014 Mar; 30(3):391-3. PubMed ID: 24164231
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
    Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
    Miller M
    Future Cardiol; 2019 Nov; 15(6):391-394. PubMed ID: 31524535
    [No Abstract]   [Full Text] [Related]  

  • 16. First-line therapies for lowering triglyceride levels.
    Raghavan VA
    Am Fam Physician; 2008 Feb; 77(4):416; author reply 417-8. PubMed ID: 18326158
    [No Abstract]   [Full Text] [Related]  

  • 17. History and future of omega-3 fatty acids in cardiovascular disease.
    Sperling LS; Nelson JR
    Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease.
    Brinton EA
    Cardiol Clin; 2015 May; 33(2):309-23. PubMed ID: 25939302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
    Med Lett Drugs Ther; 2020 Feb; 62(1591):17-18. PubMed ID: 32022786
    [No Abstract]   [Full Text] [Related]  

  • 20. Refining the American guidelines for prevention of cardiovascular disease - Authors' reply.
    Ridker PM; Cook NR
    Lancet; 2014 Feb; 383(9917):600. PubMed ID: 24529467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.